Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Moderna’s COVID-19 vaccine may not respond as well against South African variant

By Chris Newmarker | January 25, 2021

Moderna

Moderna Logo (PRNewsFoto/Moderna Therapeutics)

Moderna (NSDQ:MRNA) announced today that it will start a Phase 1 study in the U.S. of an emerging variant vaccine booster candidate against a new COVID-19 variant out of South Africa. The company will also test an additional booster of its present vaccine.

The Cambridge, Mass.–based company said it has observed a sixfold reduction in neutralizing antibodies that its COVID-19 vaccine produces against the South African variant compared to earlier strains. But it still expects the two-dose regimen of its vaccine to be protective against emerging strains detected to date.

The in vitro neutralization studies, which involved sera from individuals vaccinated with Moderna’s vaccine, found no significant reduction in neutralizing antibodies related to the variant that has emerged out of the U.K.

In general, the question of how emerging variants impact vaccine efficacy is an unsettled, although it is possible they could lead to a “numerically meaningful drop,” according to one virologist.

“As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 Vaccine should be protective against these newly detected variants,” Moderna CEO Stéphane Bancel said in a news release.

“Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants.”

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Coronavirus vaccine
9 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny
Johnson & Johnson
Feds halt J&J COVID-19 vaccine due to blood clot concern
Pfizer-BioNTech
Pfizer asks FDA to authorize its COVID-19 vaccine for younger teens
Johnson & Johnson
EMA begins investigation of J&J COVID-19 vaccine’s blood clotting potential 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards